Domov › Burkittov limfom › Distrikta Columbia › Washington

Klinične študije za Burkittov limfom v Washington, DC

9 študij za Burkittov limfom išče udeležence na lokacijah v Washington in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

MedStar Georgetown University Hospital, Washington D.C.
Children's National Medical Center, Washington D.C.
Walter Reed National Military Medical Center, Bethesda · 7 mi stran

366 Days – 46 Years · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06124157

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Vključevanje udeležencevFaza 1/2

National Institutes of Health Clinical Center, Bethesda · 7 mi stran

Starost 3–39 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT05442515

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Vključevanje udeležencevFaza 2

MedStar Georgetown University Hospital, Washington D.C.

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT03739814

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

Vključevanje udeležencevFaza 1/2

National Institutes of Health Clinical Center, Bethesda · 7 mi stran

Starost 18–120 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT03223610

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Vključevanje udeležencevFaza 2

Children's National Medical Center, Washington D.C.

365 Days · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Vključevanje udeležencevFaza 3

American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi stran

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Vključevanje udeležencevFaza 2

Children's National Medical Center, Washington D.C.

Starost 1–30 · Vsi spoli · Posodobljeno 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Vključevanje udeležencevFaza 3

Children's National Medical Center, Washington D.C.
Walter Reed National Military Medical Center, Bethesda · 7 mi stran

365 Days – 25 Years · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT03959085

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Vključevanje udeležencevFaza 1

National Institutes of Health Clinical Center, Bethesda · 7 mi stran

Starost 18–120 · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT05389423

Študije za Burkittov limfom v drugih mestih

Druge študije v Washington

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.